New aspects of influenza viruses
- PMID: 1310439
- PMCID: PMC358224
- DOI: 10.1128/CMR.5.1.74
New aspects of influenza viruses
Abstract
Influenza virus infections continue to cause substantial morbidity and mortality with a worldwide social and economic impact. The past five years have seen dramatic advances in our understanding of viral replication, evolution, and antigenic variation. Genetic analyses have clarified relationships between human and animal influenza virus strains, demonstrating the potential for the appearance of new pandemic reassortants as hemagglutinin and neuraminidase genes are exchanged in an intermediate host. Clinical trials of candidate live attenuated influenza virus vaccines have shown the cold-adapted reassortants to be a promising alternative to the currently available inactivated virus preparations. Modern molecular techniques have allowed serious consideration of new approaches to the development of antiviral agents and vaccines as the functions of the viral genes and proteins are further elucidated. The development of techniques whereby the genes of influenza viruses can be specifically altered to investigate those functions will undoubtedly accelerate the pace at which our knowledge expands.
Similar articles
-
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.J Virol. 2015 Mar;89(5):2820-30. doi: 10.1128/JVI.03246-14. Epub 2014 Dec 24. J Virol. 2015. PMID: 25540378 Free PMC article.
-
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.J Virol. 2017 Nov 14;91(23):e01579-17. doi: 10.1128/JVI.01579-17. Print 2017 Dec 1. J Virol. 2017. PMID: 28931689 Free PMC article.
-
Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.J Virol. 2018 Oct 29;92(22):e01323-18. doi: 10.1128/JVI.01323-18. Print 2018 Nov 15. J Virol. 2018. PMID: 30185589 Free PMC article.
-
Prophylaxis and treatment of influenza virus infection.BioDrugs. 2001;15(5):303-23. doi: 10.2165/00063030-200115050-00003. BioDrugs. 2001. PMID: 11437694 Review.
-
[Live cold-adapted influenza vaccine: state-of-the-art].Vopr Virusol. 2011 Jan-Feb;56(1):4-17. Vopr Virusol. 2011. PMID: 21427948 Review. Russian.
Cited by
-
Gene Expression and Antiviral Activity of Interleukin-35 in Response to Influenza A Virus Infection.J Biol Chem. 2016 Aug 5;291(32):16863-76. doi: 10.1074/jbc.M115.693101. Epub 2016 Jun 15. J Biol Chem. 2016. PMID: 27307042 Free PMC article.
-
Isolation of influenza virus in human lung embryonated fibroblast cells (MRC-5) from clinical samples.J Clin Microbiol. 1995 Jul;33(7):1948-9. doi: 10.1128/jcm.33.7.1948-1949.1995. J Clin Microbiol. 1995. PMID: 7665680 Free PMC article.
-
Cell-based influenza vaccines: progress to date.Drugs. 2008;68(11):1483-91. doi: 10.2165/00003495-200868110-00002. Drugs. 2008. PMID: 18627206 Review.
-
Evidence for two-stage binding by the 175-kD erythrocyte binding antigen of Plasmodium falciparum.J Exp Med. 1993 Nov 1;178(5):1497-505. doi: 10.1084/jem.178.5.1497. J Exp Med. 1993. PMID: 8228803 Free PMC article.
-
An overview of the highly pathogenic H5N1 influenza virus.Virol Sin. 2013 Feb;28(1):3-15. doi: 10.1007/s12250-013-3294-9. Epub 2013 Jan 16. Virol Sin. 2013. PMID: 23325419 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous